Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

6.740 +0.270 (+4.17%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 617,565
Open 6.900
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 6.470
Today's Range 6.740 - 6.920
52wk Range 4.790 - 8.580
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation
Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients. 
Via Benzinga
Exposures Product Safety
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish
Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very... 
Via Stocktwits

Performance

YTD
+36.4%
+36.4%
1 Month
+14.8%
+14.8%
3 Month
+23.7%
+23.7%
6 Month
-0.3%
-0.3%
1 Year
-11.3%
-11.3%

More News

Read More
Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards
Via Benzinga
Topics Earnings
Exposures Financial
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Via Benzinga
Exposures Product Safety
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Via Benzinga
Exposures Product Safety
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
Bayer Seeks European Approval For Its Menopause Drug
Via Benzinga
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Via Benzinga
Week In Review: Zenas Raises $259 Million In IPO
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Via Investor's Business Daily
“Signing Day Sports, Inc. (NYSE American: SGN) Soars in Pre-Market on Acquisition News – see more penny stocks inside….”
Via AB Newswire
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study
Via Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Via Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Via Benzinga
BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
Via Benzinga
Topics Lawsuit
Exposures Financial Glyphosate Legal
ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
Via MarketBeat
Topics Cannabis
Exposures Cannabis
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
Via InvestorPlace
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
Via Benzinga
Exposures Glyphosate
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Via Benzinga
Topics Data Breach
Exposures Information Security
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Via Benzinga

Frequently Asked Questions

Is Bayer Aktienges ADR publicly traded?
Yes, Bayer Aktienges ADR is publicly traded.
What exchange does Bayer Aktienges ADR trade on?
Bayer Aktienges ADR trades on the OTC Traded
What is the ticker symbol for Bayer Aktienges ADR?
The ticker symbol for Bayer Aktienges ADR is BAYRY on the OTC Traded
What is the current price of Bayer Aktienges ADR?
The current price of Bayer Aktienges ADR is 6.740
When was Bayer Aktienges ADR last traded?
The last trade of Bayer Aktienges ADR was at 05/02/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.